January 19, 2013
TOPIC: Featured News, Patients & Members, Advocacy, Industry
Orphan Drug Act at 30: Will Success Become Too Expensive?
Posted by
Reprinted with permission from FDA Matters: By Steven Grossman
The Orphan Drug Act (ODA) turned 30 this month, demonstrating that good laws really can have an enduring impact. Amidst the celebrations, a reporter asked me a provocative question: Can we afford more orphan drugs costing hundreds of thousands of dollars per year? FDA Matters answered “yes”…. Read More